X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA NOVARTIS ELDER PHARMA/
NOVARTIS
 
P/E (TTM) x -0.2 295.1 - View Chart
P/BV x 0.1 25.1 0.4% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 ELDER PHARMA   NOVARTIS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
NOVARTIS
Mar-17
ELDER PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs380855 44.4%   
Low Rs188666 28.2%   
Sales per share (Unadj.) Rs491.2219.0 224.3%  
Earnings per share (Unadj.) Rs-3.219.1 -16.7%  
Cash flow per share (Unadj.) Rs14.420.3 71.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.3 0.0%  
Book value per share (Unadj.) Rs376.5307.0 122.7%  
Shares outstanding (eoy) m20.5429.96 68.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.5 16.7%   
Avg P/E ratio x-89.339.8 -224.2%  
P/CF ratio (eoy) x19.737.5 52.6%  
Price / Book Value ratio x0.82.5 30.5%  
Dividend payout %052.4 0.0%   
Avg Mkt Cap Rs m5,83322,779 25.6%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m2,1791,393 156.4%   
Avg. sales/employee Rs ThNM9,736.2-  
Avg. wages/employee Rs ThNM2,066.8-  
Avg. net profit/employee Rs ThNM849.0-  
INCOME DATA
Net Sales Rs m10,0896,562 153.7%  
Other income Rs m257702 36.6%   
Total revenues Rs m10,3467,264 142.4%   
Gross profit Rs m-792259 -305.9%  
Depreciation Rs m36136 1,006.4%   
Interest Rs m2,7567 38,281.9%   
Profit before tax Rs m-3,653917 -398.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125345 36.3%   
Profit after tax Rs m-65572 -11.4%  
Gross profit margin %-7.83.9 -198.9%  
Effective tax rate %-3.437.6 -9.1%   
Net profit margin %-0.68.7 -7.4%  
BALANCE SHEET DATA
Current assets Rs m9,2409,731 95.0%   
Current liabilities Rs m9,9981,830 546.2%   
Net working cap to sales %-7.5120.4 -6.2%  
Current ratio x0.95.3 17.4%  
Inventory Days Days4649 95.1%  
Debtors Days Days6025 238.3%  
Net fixed assets Rs m10,12457 17,698.8%   
Share capital Rs m206141 146.2%   
"Free" reserves Rs m5,5829,056 61.6%   
Net worth Rs m7,7349,196 84.1%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88211,499 199.0%  
Interest coverage x-0.3128.4 -0.3%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 77.3%   
Return on assets %11.85.0 233.4%  
Return on equity %-0.86.2 -13.6%  
Return on capital %22.310.1 221.9%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m307129 237.9%   
Fx outflow Rs m1251,734 7.2%   
Net fx Rs m181-1,605 -11.3%   
CASH FLOW
From Operations Rs m11,754-380 -3,097.3%  
From Investments Rs m-5614,208 -13.3%  
From Financial Activity Rs m-6,762-3,318 203.8%  
Net Cashflow Rs m4,432510 868.8%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 16.8 1.6 1,050.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 21.5 167.9%  
Shareholders   16,479 41,647 39.6%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS